Zenvara US Launch Plan — Year 1
Executive summary
Zenvara (zenvalimab) launches in the United States the week of May 5, 2025 for first-line treatment of metastatic non-small-cell lung cancer in patients with PD-L1 expression ≥ 50%. Year-one US net revenue forecast is $340M against an addressable patient population of approximately 24,000 first-line NSCLC PD-L1-high patients. The plan assumes Q2 formulary parity at the top three commercial pharmacy benefit managers, NBRx inflection by week 14 post-launch, and 78% lives covered (commercial + Medicare Part D) by year-end.
Launch is structured around three phases: Q1 (weeks 1-13) on uptake and awareness; Q2-Q3 (weeks 14-39) on access broadening and field expansion; Q4 (weeks 40-52) on share-of-voice in 2L preparation. The plan is internally calibrated against a defined success ladder — see the success metrics section below — with quarterly executive reviews convened by the launch lead.
Indication and label
Zenvara is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors express PD-L1 at a tumor proportion score of at least 50%, as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
Dosing is a fixed 480 mg intravenous infusion every six weeks. The Q6W cadence is a material commercial differentiator vs. the Q3W competitor standard. The compliance and clinic-throughput implications are reflected in the field force segmentation and the patient-support program design.
FDA approval was granted on March 21, 2025 with a standard PDUFA action date. The pivotal evidence is the ZENITH-1 trial (NCT04xx, n=684) — first-line monotherapy vs. pembrolizumab, primary endpoint OS (HR 0.78, 95% CI 0.66-0.92, p=0.003), median OS 24.7 vs. 19.4 months, with PFS and ORR secondary endpoints both reaching statistical significance.
Commercial objectives
Year 1: Reach 24% NBRx share in the indicated population by week 52. Establish reimbursement at all top-10 commercial plans and 7 of 10 largest Part D plans. Build a queryable HCP knowledge base of 4,200 prescriber-level interactions per quarter through Veeva CRM.
Year 2: Expand into 2L following the IMpact-2 readout (expected Q3 2026). Achieve 38% NBRx share. Pull through state Medicaid PDL placements in 12 priority states.
Year 3: Defend share through the IRA Maximum Fair Price negotiation cycle. Sustain net price erosion below 8% YoY through volume offsets and the patient access scheme to be negotiated with NICE and G-BA.
Patient access strategy
Three concentric access programs sit underneath Zenvara at launch. The Zenvara Patient Access Program (ZPAP) is the manufacturer-funded bridge for commercially insured patients during PA processing — up to 90 days of free product, no income test. The Zenvara Co-Pay Assistance Program covers commercial-plan patient out-of-pocket up to $20,000 per year, excluding government beneficiaries. And the Zenvara Quick Start Program ships product to specialty pharmacies on receipt of a clean PA decision, target 48-hour turnaround from PA approval to patient.
All three programs route through CoverMyMeds for digital PA submission and through AssistRx for benefits investigation. Performance is reviewed monthly against a 7-day Time-to-Therapy target with a hard escalation at 14 days.
Field force deployment
Field force is sized at 142 dedicated oncology reps plus 24 key account managers (KAMs) covering integrated delivery networks, plus 18 medical science liaisons (MSLs) under medical affairs governance. Geographic alignment is 27% Northeast, 24% Southeast, 22% Midwest, 27% West — matched to disease prevalence rather than to insurance lives.
Each rep carries a target list of approximately 70 oncology HCPs segmented by decile (decile 8-10 = Tier 1, 5-7 = Tier 2, 1-4 = Tier 3). Tier 1 HCPs are reached twice per quarter in person plus once virtually; Tier 2 are reached once in-person and once virtually; Tier 3 are virtual only with a monthly email cadence. The cadence is governed by the Field Force Activity Playbook (v3.x) maintained by Sales Operations.
KAMs cover 64 IDN systems representing approximately 38% of US oncology infusion volume. KAM responsibilities cover formulary pull-through, P&T committee education, and oncology pathway placement (NCCN, OneOncology, US Oncology Network, McKesson Oncology Pathways).
Payer access plan — Q1
At launch, Zenvara is covered without prior authorization at zero major commercial plans. We expect a 10-12 week PA cycle at the top five commercial plans before tier placement is settled. The payer-engagement plan front-loads contracting discussions in March-May with UHC, Anthem/Elevance, Aetna/CVS, Cigna/Evernorth, Humana, Centene, and the four major BCBS regional plans. Contract terms target tier 3 preferred with PA only, no step-therapy through pembrolizumab; we will accept a step-therapy carve-out at any plan that requires it as a fallback.
On Medicare Part D, formulary placement decisions are bid-driven for the 2026 plan year. CMS bid submissions are due June 6, 2025 (PY2026). Zenvara is positioned for inclusion in 22 of the 25 largest Part D plans based on preliminary discussions; the three exceptions (Humana Walmart Value, AARP Saver Plus, Wellcare Value Script) are low-priority by revenue.
Quarterly milestones
Q1 (weeks 1-13): PA workflow live at top-25 IDNs by week 6. First commercial sales force training PRC review by week 4. Reach 95% of Tier 1 HCPs at least once. Establish KAM coverage of 50 of 64 priority IDN systems. Land first DSE (district sales event) in each of the six regions.
Q2 (weeks 14-26): Achieve tier 3 preferred status at UHC, Aetna, Cigna for commercial book. Inflection point on NBRx (week 14 target). Begin transition to broader rep targeting beyond Tier 1.
Q3 (weeks 27-39): Pull through ESMO data presentation in field. Cigna and ESI commercial NPF refresh decisions land in late Q3 for 2026 effective date. Renegotiate per-claim rebate terms with the top three PBMs based on YTD volume.
Q4 (weeks 40-52): Hit 78% lives covered (commercial + Medicare Part D). Close out year-one launch metrics for board review. Begin 2L launch planning conditional on IMpact-2 readout.
Forecast assumptions
Year-one NBRx forecast: cumulative 7,200 patient starts (8% conversion of addressable population). Average duration on therapy 11.4 months (Kaplan-Meier estimate from ZENITH-1). Annualized net revenue per patient: $187,000 (after gross-to-net of 28%, reflecting commercial + Medicare Part D + Medicaid mix).
Sensitivity: A 200 bps miss on PA turnaround (5 days → 7 days at top commercial plans) reduces year-one revenue by approximately $34M. A delayed Cigna formulary win (Q4 vs Q1 2026 effective) reduces year-one revenue by approximately $52M. A negative Aetna 2026 formulary refresh (tier 4 with step-edit) would cost approximately $41M in year-two but is not modeled in year-one.
Risks
Step-edit imposition by ESI in commercial NPF refresh (probability: 35%, est. revenue impact: -$28M YoY). Anthem closed formulary in 4 states (probability: 60%, est. -$11M). UHC PA latency drift if utilization-management vendor transitions (low probability but uncapped downside). Competitor X (BMS CheckMate-X) phase 3 readout positive in 2026 (probability: 65%, est. -$18M defensive spend).
Mitigation: Bridge program (ZPAP) funded through Q3 to cover access transitions. KAM playbook for ESI step-edit appeal letter pre-loaded. Defensive messaging tested through MAR and pre-cleared. Weekly launch tracker established with -10% deviation alert threshold against plan.
Success metrics
Tier 1 metric — Year 1 revenue $340M ± 8% ($313M-$367M). Tier 2 metrics — Cumulative NBRx 7,200 ± 10%; Week-14 NBRx inflection achieved; Tier 3 preferred status at top 5 commercial plans by week 26; 78% lives covered by week 52. Tier 3 metrics — Average Time-to-Therapy ≤ 7 days; PA approval rate ≥ 82%; HCP unaided awareness ≥ 76% by week 26; sample-drop redemption rate ≥ 58% in oncology.
Governance
Weekly: launch tracker review every Friday led by the launch lead, with regional sales directors, market access director, MSL lead, and CI analyst. Monthly: executive review with CCO and VP Commercial. Quarterly: board update with revenue, share, access, and forecast variance.
Escalations: any single-week regional NBRx variance > -10% vs. plan triggers a same-day review with the regional sales director and market access. Any tier-change at a top-10 plan triggers an immediate convened call with market access and commercial leadership.
Cross-references
Field Force Activity Playbook v3.2 (1B5…), 2026 US Payer Landscape Brief (1D2…), HTA Evidence Gap Report (1J4…), Formulary Win/Loss Log (1E7…), Weekly Launch Tracker (1A2…).